ASMB logo

Assembly Biosciences (ASMB) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 December 2010

Indexes:

Not included

Website:

http://www.assemblybio.com

Description:

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company is developing oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and a new class of oral synthetic live biotherapeutic candidates for microbiome-related disorders. It is involved in the development of core inhibitors that suppress the functional activity of the HBV core protein at various stages of the virus life cycle. The company was previously known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

Key Details

Price

$16.83

Market Cap

$106.98 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$7.16 M

Annual EPS

-$13.38(+42.03% YoY)

PE Ratio

-

Annual ROE

-98.95%

Annual Debt To Equity

0.00

Beta

1.07

Events Calendar

Earnings

Next earnings date:

Mar 28, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Mar 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 12, 2024

Analyst ratings

Recent major analysts updates

20 June '24 HC Wainwright & Co.
Neutral
13 June '24 HC Wainwright & Co.
Neutral
01 Apr '24 HC Wainwright & Co.
Neutral
24 Mar '23 HC Wainwright & Co.
Neutral
16 Nov '22 Mizuho
Buy
24 Oct '22 Truist Securities
Hold
01 Apr '22 Truist Securities
Buy
13 Sept '21 HC Wainwright & Co.
Neutral
02 Sept '21 William Blair
Market Perform
10 May '21 SVB Leerink
Market Perform

Screeners with ASMB included

Small cap stocks
NASDAQ earnings calendar
Biggest stock gainers today
Stocks above SMA 50
Stocks with high beta
Stocks below analysts price target
Most recommended stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$16.83
ASMB price is $16.83

Price YTD Change

+71.04%
ASMB price is up +71.04% since January 1st

Price All-time High

$1215.00
ASMB price is currently -98.61% below its historical high of $1215.00

Price Analysts Target

$35.50
ASMB price is currently -52.59% lower than the consensus analysts' forecast

Market Cap

$106.98 M
ASMB market capitalization is $106.98 million

Beta

1.07
ASMB beta is 1.07

200-day SMA

$14.73
ASMB 200-day simple moving average is currently +14.24% above its 200-day simple moving average

14-day RSI

55.51
ASMB 14-day relative strength index is 55.51

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-90.94%
ASMB annual revenue is down -90.94% over the past 3 years

Annual Revenue Estimate

$28.21 M
ASMB annual revenue is currently -74.61% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

+1.49%
ASMB annual net profit is up +1.49% over the past 3 years

Annual EPS 3-Year Change

+36.29%
ASMB annual earnings per share is up +36.29% over the past 3 years

Annual EPS Estimate

-$6.87
ASMB annual earnings per share is currently +94.76% higher than the consensus analysts' forecast

Annual Operating Profit

-$64.65 M
ASMB annual operaing income is -$64.65 million

Annual Operating Profit 3-Year Change

+0.2%
ASMB annual operaing income is up +0.2% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Operating Margin Sector Rank

21.43%
ASMB annual operating profit margin is higher than 21.43% of companies in Healthcare sector

Annual Net Margin Sector Rank

22.1%
ASMB annual net profit margin is higher than 22.1% of companies in Healthcare sector

Annual ROE

-98.95%
ASMB annual return on equity is -98.95%

Annual ROA

-51.32%
ASMB annual return on assets is -51.32%

Annual EBIT

-$64.65 M
ASMB annual earnings before interest & taxes is -$64.65 million

Annual EBITDA

-$64.20 M
ASMB annual earnings before interest, taxes, depreciation & amortization is -$64.20 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

74.1%
ASMB price to book ratio is higher than 74.1% of companies in Healthcare sector

PS Ratio Sector Rank

53.28%
ASMB price to sales ratio is higher than 53.28% of companies in Healthcare sector

Enterprise Value

$79.97 M
ASMB enterprise value is $79.97 million

Enterprise Value 1-Year Change

+270.66%
ASMB enterprise value is up +270.66% year-on-year

EV/EBITDA

-1.73
ASMB EV/EBITDA is -1.73

EV/EBITDA Sector Rank

41.05%
ASMB EV/EBITDA is higher than 41.05% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

47.84%
ASMB annual debt to equity ratio is higher than 47.84% of companies in Healthcare sector

Annual Current Ratio

3.41
ASMB annual current ratio is 3.41

Annual Current Ratio Sector Rank

50.83%
ASMB annual current ratio is higher than 50.83% of companies in Healthcare sector

Annual Total Assets

$136.82 M
ASMB annual total assets is $136.82 million

Annual Current Assets

$133.79 M
ASMB annual total current assets is $133.79 million

Annual Total Liabilities

$95.73 M
ASMB annual total liabilities is $95.73 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+136.12%
ASMB annual cash flow from operations is up +136.12% over the past 3 years

Annual CFI 3-Year Change

-201.57%
ASMB annual cash flow from investing activities is down -201.57% over the past 3 years

Annual CFF 3-Year Change

+81.84%
ASMB annual cash flow from financing activities is up +81.84% over the past 3 years

Annual CAPEX

$255.00 K
ASMB annual capital expenditures is $255.00 thousand

Annual CAPEX 3-Year Change

-88.51%
ASMB annual capital expenditures is down -88.51% over the past 3 years

Annual FCF

$22.49 M
ASMB annual free cash flow is $22.49 million

Annual FCF 3-Year Change

+134.5%
ASMB annual free cash flow is up +134.5% over the past 3 years

Institutional Ownership

Similar stocks

ANIX logo
Anixa Biosciences (ANIX)
VERU logo
Veru (VERU)
AKYA logo
Akoya Biosciences (AKYA)
MIST logo
Milestone Pharmaceuticals (MIST)
QIPT logo
Quipt Home Medical (QIPT)
KPTI logo
Karyopharm Therapeutics (KPTI)
IMUX logo
Immunic (IMUX)
FONR logo
FONAR (FONR)
INMB logo
INmune Bio (INMB)
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
ASMB
globenewswire.com15 July 2024

– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
ASMB
globenewswire.com10 June 2024

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
ASMB
globenewswire.com22 May 2024

-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D --

5 Penny Stocks With Big Black Friday Stock Market News
5 Penny Stocks With Big Black Friday Stock Market News
5 Penny Stocks With Big Black Friday Stock Market News
ASMB
PennyStocks24 November 2023

Penny stocks, defined as stocks trading under $5 per share, offer investors the allure of exponential growth. As an inherently volatile market sector, penny stocks can rapidly surge on positive news, rumors, and breakthroughs – allowing traders to potentially lock in short-term gains.

Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
ASMB
InvestorPlace17 October 2023

Assembly Biosciences (NASDAQ: ASMB ) stock is taking off on Tuesday after announcing a massive collaboration with Gilead Sciences (NASDAQ: GILD ). According to a press release, these two companies have entered into a 12-year partnership agreement.

FAQ

  • What is the primary business of Assembly Biosciences?
  • What is the ticker symbol for Assembly Biosciences?
  • Does Assembly Biosciences pay dividends?
  • What sector is Assembly Biosciences in?
  • What industry is Assembly Biosciences in?
  • What country is Assembly Biosciences based in?
  • When did Assembly Biosciences go public?
  • Is Assembly Biosciences in the S&P 500?
  • Is Assembly Biosciences in the NASDAQ 100?
  • Is Assembly Biosciences in the Dow Jones?
  • When was Assembly Biosciences's last earnings report?
  • When does Assembly Biosciences report earnings?
  • Should I buy Assembly Biosciences stock now?

What is the primary business of Assembly Biosciences?

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company is developing oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and a new class of oral synthetic live biotherapeutic candidates for microbiome-related disorders. It is involved in the development of core inhibitors that suppress the functional activity of the HBV core protein at various stages of the virus life cycle. The company was previously known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.

What is the ticker symbol for Assembly Biosciences?

The ticker symbol for Assembly Biosciences is NASDAQ:ASMB

Does Assembly Biosciences pay dividends?

No, Assembly Biosciences does not pay dividends

What sector is Assembly Biosciences in?

Assembly Biosciences is in the Healthcare sector

What industry is Assembly Biosciences in?

Assembly Biosciences is in the Biotechnology industry

What country is Assembly Biosciences based in?

Assembly Biosciences is headquartered in United States

When did Assembly Biosciences go public?

Assembly Biosciences's initial public offering (IPO) was on 17 December 2010

Is Assembly Biosciences in the S&P 500?

No, Assembly Biosciences is not included in the S&P 500 index

Is Assembly Biosciences in the NASDAQ 100?

No, Assembly Biosciences is not included in the NASDAQ 100 index

Is Assembly Biosciences in the Dow Jones?

No, Assembly Biosciences is not included in the Dow Jones index

When was Assembly Biosciences's last earnings report?

Assembly Biosciences's most recent earnings report was on 7 November 2024

When does Assembly Biosciences report earnings?

The next expected earnings date for Assembly Biosciences is 28 March 2025

Should I buy Assembly Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions